Platelets activated during myocardial infarction release functional miRNA which can be taken up by endothelial cells and regulate ICAM1 expression.
Introduction
Acute coronary syndrome (ACS), including acute myocardial infarction (AMI) and unstable angina, is the result of destabilization of an atherosclerotic plaque in a coronary artery 1 . The subsequent exposure and release of sub-endothelial factors (e.g. collagen and von Willebrand Factor) trigger activation of platelets in the vicinity of the lesion 2 . Activated platelets in turn release a multitude of substances affecting the chemotactic, adhesive and proteolytic properties of endothelial cells 3, 4 .
Although platelets lack nuclei, they do retain a specific set of megakaryocyte mRNAs 5, 6 and are capable of de novo protein synthesis [7] [8] [9] . Protein translation in platelets has been shown to be under posttranscriptional control 9, 10 . In addition to having protein coding transcripts a recent report revealed that platelets contain more than 170 different microRNA (miRNA) species as well as the enzymes required to convert precursor miRNA into mature miRNA 11 . miRNAs are short (19-25 nucleotides) , non-coding RNA species which play a crucial role in regulating post transcriptional gene expression through binding to the 3' untranslated region (3'-UTR) of target mRNAs 12 . miR-96 has been shown to regulate the expression of VAMP8, a critical v-SNARE involved in platelet granule secretion 13 , indicating a functional role of miRNA in regulating platelet mRNA translation.
The concept of exovesicle mediated transfer of miRNA to the endothelium has been explored in recent studies. For example, transfer of miR-126 between endothelial cells via apoptotic bodies was shown to limit atherosclerosis, promote incorporation of progenitor cells and increase plaque stability in a mouse model through targeting RGS16 and increasing production of CXCL12 14 .
Moreover, a recent study 15 demonstrated that monocyte-derived exosomes carrying miR-150 were taken up by endothelial cells enhancing cell migration.
The aim of this work was (1) to screen for differences in miRNA content in platelets of patients diagnosed with ST-elevation myocardial infarction (STEMI) and healthy individuals, (2) to investigate the possible release and transfer of miRNAs from activated platelets to endothelial cells and (3) to assess the role of platelet-derived miRNAs in the endothelium.
Methods

Patients and samples
Patients diagnosed with STEMI were recruited during 2010 at the coronary care unit at Skane University Hospital. Diagnoses were based on ECG criteria.
Isolation and preparation of platelets, plasma and thrombi
The procedure for platelet preparation has been described in detail elsewhere 6 .
Briefly, 100 ml of blood was drawn by self-propagated flow, platelet poor plasma was passed through a Pall Autostop Leukocyte removal filter (Pall Incorporated, NY, USA) and depleted of additional leukocytes and erythrocytes using dynabeads (Dynal, Oslo, Norway) conjugated with anti-CD235a and anti-CD45 (Becton Dickinson, Franklin Lakes, NJ, USA). Plasma was prepared by centrifugation of whole blood for 15 minutes at 1600*g. For a detailed protocol of platelet and thrombi preparation, see Supplemental Methods.
RNA preparation
Cells and plasma/cell supernatants were mixed with Qiazol and TRIzol LS (Life Technologies (Carlsbad, CA, USA), respectively, and RNA was prepared using the miRNeasy mini kit (Qiagen, Hilden, Germany). For miRNA and mRNA analysis, cDNA was synthesized using the miRCURY LNA Universal RT microRNA cDNA kit (Exiqon, Vedbaek, Denmark) and the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA), respectively.
RNA-seq
Platelet RNA samples from two male STEMI patients and two age and sex matched healthy controls were prepared using the Small RNA Sample Preparation Kit (Illumina, CA, USA). Sequencing was performed on the Illumina GAIIx with a read length of 36nt. miRNA sequences iwere dentified using miRanalyzer 16 based on the bowtie architecture. The number of unique reads were counted, normalized to transcript size and expressed relative to the total number of reads.
qRT-PCR
miRNA levels were assessed by qRT-PCR using microRNA LNA Primer sets (Exiqon) specific for hsa-miR-16, -22, -126, -185, -320b, 423-5p, U6 snRNA and cel-miR-39-5p. mRNA levels for ICAM1 and Cyclophilin were analyzed with TaqMan Assays (Life Technologies). See Supplemental Methods for details.
Confirmation of deep sequencing results by qRT-PCR
Platelet RNA was prepared as described above from STEMI patients (n=10) and healthy controls (n=15). The level of U6 RNA was unaltered in STEMI patients compared to controls (CV=8.02%, Supplemental Figure 1 ) and was therefore considered reliable for normalization of platelet miRNA data.
Assessment of miRNA release from aggregated platelets
Platelets were preincubated 5 minutes with 0,25 mg/ml fibrinogen before addition of 1 U/ml of thrombin. Platelets were allowed to aggregate for 5 minutes, then centrifuged and an aliquot of the supernatant was taken. Before cDNA synthesis an exogenous miRNA spike-in (Exiqon) was added to the RNA preparations. The levels of the different miRNAs in the supernatant was normalized to the exogenous RNA spike-in.
Immunofluorescence staining of coronary thrombi
See Supplemental Methods.
Cell culture
Transfer of miRNA between platelets and endothelial cells
The procedure for transfecting platelets were based on the protocol by Hong et al (2011) 17 
miRNA levels in HMEC-1 co-cultured with platelets
HMEC-1 were seeded in 96-well plates and co-cultured with washed platelets as described. HMEC-1 were harvested at 0, 1, 3, 8 and 24 hours after addition of thrombin. RNA was prepared and the levels of each miRNA relative to miR-16 was determined. miR-16 was unaffected by thrombin during the time course (CV=11,09 %).
Assessment of platelet microparticles
Platelets transfected with miR-Scr-FITC were seeded in TAB in a 96-well plate at ~1*10 5 platelets/well. 10 ug/ml brefeldin A was added and the platelets were incubated for 30 minutes. 1 U/ml thrombin was added and the platelets were incubated for 20 minutes. Platelets were stained with CD42a-PE, fixed with 0,5 % PFA and run on a Accuri C6 flow cytometer. The microparticle population was defined first on size using 800 nm latex beads (Sigma-Aldrich, St Louise, MO, USA) and subsequently on the expression of CD42a. A PE-conjugated isotype control antibody was used to set the CD42a-gate. Mean fluorescence in FL-1 within the microparticle gate was used to assess FITC + microparticles.
A screening was performed on three compounds reported to inhibit microparticle or exosome release: Brefeldin A 18 , Cyclosporin A 19 and caspase inhibitor 20 . 10 ug/ml of Brefeldin A (Sigma), 10 uM Cyclosporin A (Sigma) and 100 uM caspase inhibitor (Ac-DEVD-CHO, Promega) were added to platelet rich plasma for 30 minutes at 37 °C before the addition of 1 U/ml Thrombin for 20 minutes and microparticles were detected by flow cytometry. 
Stimulation of HMEC-1 with platelet releasate
Platelets were incubated in 25 µM N-terminal thrombin receptor fragment SFLLRN (Bachem, Bubendorf, Swizerland) for 20 minutes at room temperature.
Aggregated platelets were pelleted and the platelet releasate was collected and stored at -80 C.
HMEC-1 were seeded in 12-well plates and after 24 hours, fresh medium with or without 20% platelet releasate containing 0 or 100 nM of Anti-miR miRNA Inhibitor (Life Technologies) corresponding to miR-22, -185, -320b or -423-5p, was added. After another 24 hours, the cells were harvested by addition of Qiazol.
Overexpression of miR-320b in HMEC-1
Statistical analysis
All statistical analyses were performed in Prism v. 4.0b (GraphPad Software Inc., CA, USA). Data represent the mean  SEM and were analyzed by Student's t test, one or two way ANOVA with Tukey post hoc analysis as appropriate. Statistical significance was considered where p<0.05.
Ethics
This study was conducted according to the principles of the Declaration of Helsinki and was approved by the local ethics commitee of Skåne University Hospital. All patients gave their written approval before participation.
Results
Altered platelet miRNA profile in STEMI patients
We performed RNA-seq of platelet miRNA in two STEMI patients as well as in two age and sex matched healthy individuals. The mean number of total transcripts detected was 136 670 and mean of 109 different miRNA species were detected in the samples. The twenty most highly expressed miRNAs in each individual is presented in Table 2 . The complete miRNA profiles can be found in Supplemental Table 1 . The levels of nine different miRNA species were significantly altered between patients and controls (Supplemental Figure 5 ). Of these, miR-320a was upregulated whereas all the other miRNAs were lower in patients than in controls. Possible mRNA targets of these miRNAs were assessed with TargetScan (v. 5.1) and four candidate miRNAs; miR-22, -185, -320b and -423-5p were selected for further evaluation ( Table 1 ). The criteria for selection were based on: (i) the potential relevance to atherosclerosis or inflammation (ii) the relative abundance in platelets and (iii) the magnitude of the difference between patients and controls. To validate the findings indicated by RNA-seq the levels of the four selected miRNAs were determined in the platelets from STEMI patients (n=10) and from healthy controls (n=15) ( Figure 1a ). The results demonstrated an approximately 70-90% decrease of all the four miRNAs in STEMI patients (p<0.01), thus confirming the results of the RNA-seq.
Platelets release miRNAs upon aggregation
The fact that out of the nine differentially expressed miRNAs, eight showed decreased levels in patients led us to hypothesize that the higher level of platelet activation in STEMI patients resulted in release of platelet miRNA. To examine this, we used qRT-PCR to measure the levels of the four candidate miRNAs in the supernatant of resting platelets and platelets aggregated with 1 U/ml thrombin with qRT-PCR ( Figure 1b ). Following aggregation the levels of all four miRNAs increased in the supernatant. Although the magnitude of the increase varied between donors, from 3.1-fold (SEM=0.49) to 21-fold (SEM=7.9), the increase was significant in all of them.
To further investigate the idea of miRNA release from activated platelets, we compared the miRNA profiles of platelets from healthy individuals, STEMI patients and from coronary thrombi retrieved from the occlusion causing the STEMI (Figure 1c ). The results confirmed the previous findings as the levels of all four miRNAs were even lower in thrombi than in STEMI platelets indicating an activation-generated depletion of certain miRNAs. The presence of platelets in thrombi was confirmed by confocal microscopy (Supplemental Figure 6 ).
The levels of these miRNAs were also analyzed in the circulation of a subset of patients. miR-22 and miR-423-5p were undetectable, miR-185 was unaltered and miR-320b was slightly elevated (p=0.31, Supplemental Figure 7 ).
miRNA is transfered from platelets to endothelial cells
We hypothesized that the miRNAs released from activated platelets could be taken up by endothelial cells. To test this idea, platelets were transfected with a synthetic exogenous miRNA, syn-cel-miR-39. The efficiency of the transfection was determined by absolute qRT-PCR and while untransfected platelets were completely negative for cel-miR-39 expression transfected platelets contained ~2000 copies/platelet. Activation of transfected platelets with 1 U/ml Thrombin resulted in a 21-fold increase of cel-miR-39 in the supernatant and a corresponding 60% decrease in intracellular cel-miR-39 (Figure 2a ). In the next experiment transfected platelets were co-cultured with HMEC-1 cells for either 1 or 3 hours, in the presence or absence of 1 U/ml thrombin. After removing the platelets and washing the monolayer, cel-miR-39 levels were assessed with qRT-PCR ( Figure 2b ). It was found that while Cel-miR-39 was undetectable in HMEC-1 after one hour of co-culture (data not shown), 3 hours of co-culture produced levels that were readily detectable in HMEC-1. Furthermore, the transfer was clearly dependant on the platelet activation status as cells co-cultured with activated platelets contained 80-fold more cel-miR-39 than cells co-cultured with resting platelets.
To further confirm miRNA transfer from platelets to endothelial cells, platelets were transfected with a scrambled, fluorescently labeled miRNA (miR-Scr-FITC).
Transfected platelets were co-cultured with HMEC-1 for three hours in the Following these proof-of-concept experiments, we wanted to examine if there was an endothelial uptake of the four miRNAs that were shown to be released from platelets (miR-22, -185, -320b and -423-5). Platelets and endothelial cells were again co-cultured in the presence or absence of thrombin and the timecourse for the uptake process was measured using qRT-PCR ( Figure 3 ). In the presence of thrombin-activated platelets, there was a distinct but transient increase of all four miRNAs in the endothelial cells, peaking at either 3 or 8 hours depending on the miRNA species. However, when the experiment was repeated using resting platelets, the miRNA levels were unaffected. Expression of the endothelial cell-enriched miRNA miR-126 21 was unaffected by the presence of activated platelets (Supplemental Figure 9 ). Thrombin itself did not have any effect on miRNA levels in the endothelial cells (Supplemental Figure 10) .
Platelet miRNA is released and transfered by a vesicle-dependent mechanism
Considering the recent reports of microvesicle-dependent cell-to-cell miRNA transfer and the well established notion of microparticle release from platelets, we hypothesized that the platelet miRNAs were released in microparticles. After a screening of several compounds reported to inhibit microparticle formation, we found that Brefeldin A was the most effective microparticle inhibitor ( Figure   4a and Supplemental Figure 11 ). We then transfected platelets with fluorescently labeled miR-Scr-FITC and stimulated with thrombin in the presence or absence of brefeldin A. Fluorescent labeling of the generated microparticle fraction was then assessed with flow cytometry. There was a significant enrichment of miR-Scr-FITC in the CD42a + microparticle population after stimulation with thrombin. This effect was partly inhibited with the addition of 10 ug/ml of brefeldin A (Figure 4b ). There was also a small but significant decrease in fluorescence intensity in transfected platelets, indicating release of miR-FITC upon activation (Suplemental Figure 12 ).
To further test this, we co-cultured miR-Scr-FITC transfected platelets with HMEC-1 and activated the platelets with thrombin in the presence or absence of brefeldin A. After 3 hours of co-culture, the proportion of FITC + HMEC-1 was then assessed with confocal microscopy (Figure 4c ). In the presence of activated platelets, ~50% of the cells were FITC + (a 1.6-fold increase compared to cells cultured with untreated platelets, p<0.05). The addition of Brefeldin A significantly decreased the proportion of FITC + HMEC below the baseline, indicating that vesicle formation is required for an efficient release and transfer of miRNA from platelets to endothelial cells.
Endothelial cell gene expression is altered by activated platelets via a miRNAdependent mechanism
Finally, our aim was to investigate if the miRNAs released from activated platelets could confer any effect on target gene expression in the endothelial cells. The first step was to confirm the predicted mRNA targets of miR-22, -185, -320b and -423-5p (see Table 2 ). HEK293 cells were co-transfected with luciferase reporter plasmids containing the 3'-UTR of ICAM-1, eNOS, VEGFA and VEGFB and pre-miRNA corresponding to each of the four miRNA candidates.
Over expression of miR-22 and miR-320b caused significant dose-dependent quenching of the ICAM1 reporter signal compared to cells transfected with a scrambled pre-miR, indicating interaction of miRNA and mRNA (Figure 5a ). The remaining miRNA-target interactions could not be confirmed (data not shown) so we chose to focus the rest of the study on the interaction of miR-22 and miR-320b with ICAM1.
To investigate whether activated platelets could affect ICAM1 gene expression, HMEC-1 cells were cultured in the presence of platelet releasate. After 24 hours ICAM1 expression was downregulated by ~30% (p<0.05, Figure 5b ), supporting the hypothesis that the effect is mediated by miRNA.
To further confirm the interaction between miR-22/-320b and ICAM1 mRNA, we knocked down endogenous miRNA using anti-miRNAs corresponding to miR-22 and miR-320b and measured ICAM1 gene expression using qRT-PCR ( Figure 5c ).
As expected, knock down of these miRNAs caused a significant increase in target mRNA, by 2-(p<0.05) and 4-fold(p<0.001), respectively, compared to cells treated with a scrambled Anti-miRNA. Then, our aim was to examine whether the effect on ICAM1 expression seen when adding platelet releasate was caused by miRNAs. Platelet releasate was added to HMEC-1 cells where miR-22 and miR-320b had been suppressed using anti-miRNA. Interestingly, the effect of anti-miR-320b, but not anti-miR-22, on ICAM-1 expression was rescued by the addition of platelet releasate to the endothelial cells (p<0.01). This indicates an efficient transfer of specific functional miRNA species from the platelet releasate to the endothelial cells.
miR-320b regulates cell surface ICAM-1 expression on endothelial cells
To confirm that miR-320b can confer an effect on ICAM1 also on the protein level, HMEC-1 were transfected with synthetic precursor miRNA or scrambled pre-miRNA and cell surface bound ICAM-1 protein was quantified with flow cytometry after 48 hours. Overexpression of miR-320b was confirmed by qRT-PCR (Supplemental Figure 13 ). The ICAM1 mean fluorescence intensity decreased 7% (p<0.001) in cells overexpressing miR-320b as compared to scrambled control (Figure 5d and e), indicating a functional role of miR-320b on ICAM-1 in endothelial cells.
Discussion
The discovery of miRNA 22, 23 and the enzymatic infrastructure required to convert precursor-miRNA into mature miRNA 11 in platelets was reported recently. A few studies mapping the full platelet miRNA repertoire have been conducted since then 24,25 but to our knowledge, no one has studied the platelet miRNA transcriptome in patients with myocardial infarction. In an effort to address this question we conducted RNA-seq of highly purified platelet preparations from patients with STEMI and from healthy individuals. The dominating miRNA species in both patients and controls were miR-320a, comprising >80% of total miRNA transcripts in healthy individuals. miR-320a has been detected in platelets in previous studies but not in the same proportions as here. Overall, the platelet miRNA profiles reported so far are quite disparate. Apart from differences in method used (microarray, qRT-PCR, RNA-seq), this might relate to differences in platelet preparation, varying degrees of platelet activation or presence of contaminating leukocyte or erythrocyte miRNAs. It is worth mentioning that RNA-seq, unlike for example microarray, is not a hybridization-based technique and the results are therefore considered more unbiased 26 .
We found nine differentially expressed miRNAs in patients compared to controls of which eight were downregulated in patients. This prompted us to investigate whether general platelet activation following myocardial infarction leads to a release of miRNA from platelets. The notion of miRNA release from activated or apoptotic cells have been proposed by several groups recently. Exosomemediated transfer of miRNA have been shown in activated mast cells 27 and from T cells to antigen-presenting cells 18 . In a recent report, apoptotic bodies carrying miR-126 between endothelial cells caused upregulation of CXCL12 in recipient cells 14 . A very recent report shows that smooth muscle cells provide an atheroprotective signal to endothelial cells through vesicular transfer of miR-143/145 28 .
We could confirm release of miR-22, -185, 320b and -423-5p from ex vivo aggregated platelets and also noticed a depletion of these miRNAs in thrombi aspirated from STEMI patients. The release of platelet miRNAs was not reflected in increased overall levels in the circulation of patients. It could be argued that the release of miRNAs from activated platelets is likely to be a local event at the site of the ruptured plaque and would therefore not be detectable in the periphery. Regarding the results from the thrombi, it is possible that the relative decrease in platelet miRNAs is partly due to the dilution of platelets with other cell types in the thrombus. This may exaggerate the decline in platelet miRNAs somewhat but does not account for the total lack of miR-22, for example.
We were able to demostrate efficient transfer of both fluorescently labeled miRNA and exogenous C. Elegans miRNA from activated platelets to an endothelial cell line. Co-culture of activated platelets and endothelial cells caused a transient increase of all four platelet miRNAs, but not the endothelial cellenriched miR-126, in HMEC-1 cells. Considering that the miRNA transfer could be completely abolished with the addition of Brefeldin A, which we show to be an inhibitor of platelet microparticle release, it is likely that the miRNA release is vesicle-dependent. The effect of Brefeldin A is probably best explained by its well documented ability to disrupt vesicular transport processes 29 . Brefeldin A has recently been reported to inhibit release of exosome-like vesicles from cells 30 and to suppress exosome-dependent transfer of miRNA between immune cells 18 .
We can however not rule out that Brefeldin A also affects the endothelial uptake of miRNA. In a recent report, Diehl et al showed that platelet microparticles were enriched for distinct miRNA species 31 , which suggests that secretion of miRNAs from platelets is a selective process. Although the exact mechanism of release and uptake requires further research, recent reports on exovesicle/microparticle-mediated cell-to-cell transfer of miRNA and the wellresearched mechanism of platelet microparticle release, do strengthen this hypothesis.
We observed a decreased expression of ICAM-1 in the presence of platelet releasate and hypothesized that this effect might be mediated by released miRNA. De-repression of ICAM-1 mediated by anti-miR-320b, but not anti-miR-22, was almost completely abolished by the addition of platelet releasate. This selective effect rules against the posibility that some factor in the platelet releasate causes a general effect on the endothelium, independent of miRNA.
In contrast to the results presented herein, previous studies have reported increased endothelial ICAM-1 expression in the presence of platelet releasate through a IL-1 dependent mechanism 32, 33 . The discrepancy might be attributed to differences in the dynamics of ICAM-1 regulation. Gawaz et al (2000) reported a maximal ICAM-1 expression after 16 hours. In the present study, ICAM-1 expression was evaluated after 24 hours. It is possible that regulation of ICAM-1 expression by external miRNAs might represent an additional, regulatory mechanism, counteracting that of IL-1 in the long-term.
One might speculate that the role of platelet-derived miRNA in the endothelium might be to regulate and fine tune the effects of the pro-inflammatory mediators in the releasate. Indeed, several recent papers have proposed miRNAs as fine tuners of the inflammatory response 34, 35 .
In conclusion, we report that the platelet miRNA content of STEMI patients is distinctly different to that of healthy individuals, that miRNAs are shed from activated platelets and that platelet-derived miRNA can affect endothelial cell gene expression. 
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